


**USCOM**

ABN: 35 091 028 090



New Evidence in Breast Cancer Treatment

"Cardiac monitoring mandatory for patient safety"
"Important new application for USCOM"

Wednesday 15 November, 2006: USCOM Limited (ASX Code: UCM) today released the results of significant research into USCOM's role in the management of breast cancer.

A paper presented this week at the German National Congress For Plastic and Reconstructive Surgery, demonstrated how USCOM can assist in the management of breast cancer patients undergoing chemotherapy.

The paper states, *"Chemotherapy for metastatic breast cancer involves possible cardiotoxic agents. A thorough cardiac evaluation and monitoring during chemotherapy therefore is mandatory to increase patients' safety. Immunotherapy with trastuzumab (Herceptin), a selective HER-2(ErbB2)-antibody, is approved in women with metastatic breast cancer and is associated with a certain degree of cardiotoxicity. The study sought to evaluate the immediate hemodynamic response to drugs as a possible marker of cardiotoxicity."*

The study, conducted at the Hannover University School of Medicine, involved 75 patients with HER-2-positive metastatic breast cancer who were continuously measured with the non-invasive USCOM monitor for stroke volume (SV), cardiac output (CO), cardiac index (CI), and systemic vascular resistance (SVR) before, during and after drug infusion.


The study concludes that using by USCOM, a different haemodynamic response to the infusion of different drugs is evident in women with metastatic breast cancer.

HER2-positive breast cancer refers to a type of breast cancer in which increased quantities of the HER2 (Human Epidermal growth factor Receptor 2) protein are present on the surface of the tumour cells. This is known as 'HER2 overexpression'. High levels of HER2 overexpression are present in a particularly aggressive form of breast cancer which responds poorly to chemotherapy.

Commenting on the announcement today, USCOM's Chairman and Director of Clinical Science, Mr Rob Phillips MPhil(med), said, *"This study confirms an important new application for USCOM in evaluating the cardiac effects of therapeutic drugs. Accurately measuring cardiac function is essential during any drug therapy and we have always believed that USCOM has an important role to play in monitoring cardiac function during drug treatments, whether that be for breast cancer, hypertension or heart failure. It is exciting to see this now being demonstrated in international science."*

**USCOM**


ABN: 35 091 028 090

**About breast cancer**

Each year more than one million new cases of breast cancer are diagnosed worldwide, with a death rate of nearly 400,000 people per year. Breast cancer is the most common cancer (excluding non-melanocytic skin cancer) in Australian women. It is also the most common cause of cancer death among Australian women. One in 11 Australian women are diagnosed with breast cancer in their lifetime.

**USCOM**

ABN: 35 091 028 090

**About Herceptin**

Herceptin is a targeted humanised antibody treatment that received approval in the European Union in 2000 for use in patients with metastatic breast cancer, whose tumours overexpress the HER2 protein. It is indicated for treatment of patients both as first-line therapy in combination with Taxol and as a single agent in second- and third-line therapy.

www.uscom.com.au**USCOM Limited**Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia
Phone: 61-2-9247 4144 Fax: 61-2-9247 5157